• Already Registered?
Skip Navigation
2019 Community Oncology Conference
  • 2019 Community Oncology Conference

    The One Conference for the Whole Practice

    April 4-5, 2019

    Walt Disney World Dolphin Hotel
    Orlando, Florida
         
  •      
  •      
  •      
  •      
  •      
  • Home
    • Summary
  • About
    • Key Dates
    • Registration Pricing
    • Continuing Medical Education
    • FAQs
    • Latest Updates
    • Past COA Conferences
  • Presentations
    • Download Presentations by Agenda
  • Speakers
    • Co-Chairs
    • Keynote Speakers
    • Speakers
  • Hotel/Travel
    • Hotel Information
    • Travel
    • Discounted Disney Tickets
  • Exhibit & Sponsor
    • Overview
    • Thank You to our Exhibitors
    • Thank You to our Sponsors

Continuing Medical Education

Intended Learners

This conference is designed for community oncology providers, administrators, staff, pharmacists, nurses, and advocates addressing the unique issues facing community oncology in the real world. 


Learning Objectives


After participating in the Community Oncology Summit, participants should be able to:

  • Obtain the latest clinical updates, cutting edge treatment options, and the role of genetics in determining best path to treatment
  • Hear a discussion surrounding the value of and reimbursement for CAR-T
  • Learn strategies for managing mergers, acquisitions, and partnership agreements
  • Identify opportunities to engage with state and federal lawmakers on policymaking that affects community cancer care
  • Receive firsthand status updates from participants in the CMMI OCM, along with COA’s status of OCM 2.0
  • Advance their knowledge on the power and potential of advocacy for cancer care

Activity Overview


This interactive educational conference will occur from April 4–5, 2019 at the Walt Disney World Dolphin Hotel in Orlando, Florida. A question-and-answer session with the faculty will follow the presentations.

To be eligible for documentation of credit, participants must attend the full activity and submit a completed evaluation form. Participants who complete the evaluation online within 4 weeks of the live meeting will immediately receive documentation of credit.

Use this link to complete the required evaluation for credits: https://www.naccme.com/program/coa-2019

For questions regarding this educational activity, please call 609-371-1137.


Accreditation Information


In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME), Imedex and the Community Oncology Alliance. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physicians

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Imedex and the Community Oncology Alliance. Imedex is accredited by the ACCME to provide continuing medical education for physicians.

Imedex designates this live activity for a maximum of 12.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables a participant to earn up to 12.25 MOC points towards the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is Imedex’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC Points. The deadline to claim MOC points is May 4, 2019. ABIM Diplomates will be asked to provider their identification number and DOB.

Nursing

This continuing nursing education activity awards 12.25 contact hours

Provider approved by the California Board of Registered Nursing, Provider #13255 for 12.25 contact hours.

Pharmacy

This live, knowledge-based activity (Universal Activity Number JA0006201-9999-19-010-L01-P) has been approved for a maximum of 12.25 contact hours (1.25 CEUs)

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in CPE Monitor system. The deadline to claim credit is May 4, 2019. Following ACPE Policy, NACCME will not be able to report your claimed credit to CPE Monitor after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. For online activities, after downloading your certificate, you must make sure you click to upload your credits to CPE Monitor. Failure to do so will result in NO CREDIT AWARDED.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

ADA Statement

North American Center for Continuing Medical Education complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.

Support

The following companies have provided an educational grant in support of this conference:

Amgen      Astellas 

Novartis    Pfizer

 

The Commercial Exhibition

As a part of the conference, companies and organizations may display their products and services. The exhibition is located in Atlantic Hall B-C. Exhibitions should not be construed as an endorsement of a product or manufacturer’s claims by Imedex.

 

https://www.coaconference.com/events/2019-community-oncology-conference/custom-123-bcba460a3859463c8cbd941ff841b31f.aspx

Planning Committee

The planning committee comprises of Robert Baird, Michael Diaz, MD, David Eagle, MD, Rose Gerber, Debra Patt, MD, Jeffrey Patton, MD, and Mary Kruczynski.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME and Imedex, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME and Imedex to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

The faculty has reported the following:

Sibel Blau, MD: Speakers’ Bureau – Adaptive Health Focus Group – Cardina, Puma Biotechnology, INC, AJMC Institute of Value Based Oncology; Advisory Board - Novartis Ribo

Sean Brusky: Employee – Genentech

Roberta Buell: Owner/Board Membership - onPoint Oncology

Howard "Skip" Burris, MD: Stock Ownership/Employee – HCA Healthcare; Consultant – Mersana, AstraZeneca, FORMA Therapeutics, Janssen, Novartis, Roche/Genentech, TG Therapeutics, MedImmune, Bristol-Myers Squibb; Grant/Research Support – Roche/Genentech, Bristol-Myers Squibb, Incyte, Tarvada Therapeutics, Mersana, AstraZeneca, MedImmune, Macrogenics, Novartis, Beohringer Ingelheim, Lilly, Seattle Genetics, Abbvie, Bayer, Celldex, Merck, Celgene, Agios, Jounce Therapeutics, Moderna Therapeutics, CytomX Therapeutics, GlaxcoSmithKline, Verastem, Tesaro, Immunocore, Takeda, Millennium, BioMed Valley Discoveries, Pfizer, PTC Therapeutics, TG Therapeutics, Loxo, Vertec, eFFECTOR Therapeutics, Janssen, Gilead Sciences, Valent Technologies, BioAtla, CicloMed, Harpoon Therapeutics, Jiangsu Hengrui Medicine, Revolution Medicines, Daiichi Sankyo, H3 Biomedicine, Neon Therapeutics, OncoMed, Regeneron, Sanofi; Advisory Board – Novartis

Basit Chaudhry, MD: Stock Ownership – New Enterprise Associates; Employee – Tuple Health; Consultant – BMS, PhRMA, EviCore

Jonas Congelli, RPh: Consultant – ION Specialty Oncology Network

Josh Cox, PharmD, BCPS: Employee (Spouse) – Boehringer Ingelheim Pharmaceuticals

Michael Diaz, MD: Consultant/Stock Ownership – OTC Healthtech Group, Inc.

David Eagle, MD: Stock Ownership – Coherus, Odonate

John Frownfelter, MD: Employee – Jvion

Bo Gamble: Speakers’ Bureau – Merck

Katie Goodman, RN: Employee - Florida Cancer Specialists

Lucio Gordan, MD: Stock Ownership/Board Membership: Florida Cancer Specialists, American Oncology Network; Consultant – International Oncology Network ION

Matthew D. Hall. MD, MBA: Speakers’ Bureau – ViewRay, Inc., Accuray, Inc.; Consultant – Chrysalis Biotherapeutics

Melissa Johnson, MD: Grant/Research Support: BerGenBio, Lilly, EMD Serono, Janssen, Mirati Therapeutics, Genmab, Pfizer, AstraZeneca, Genentech / Roche, Stemcentrix, Novartis, Checkpoint Therapeutics, Array BioPharma, Regeneron, Apexigen, Abbvie, Tarveda, Adaptimmune, Syndax, Neovia, Boehringer Ingelheim, Sanofi, Hengrui Therapeutics, INC, Merck, Daiichi – Sankyo, Lycera, G1 Therapeutics, Dynavax, LOXO, Cytomx, BeiGene, Birdie, Corvus, Incyte, Genocea, Gritstone, Amgen, Bristol Myers Squibb, Kadmon, Clovis, Acerta, OncoMed, Guardant Health; Advisory Board (Self) – Genentech/Roche, Celgene, Boehringer Ingelheim, Sanofi, Mirati, LOXO, Calithera, AstraZeneca, Merck, Araxes Pharma, Mersana Therapeutics, BeiGene, Incyte, Pfizer, Guardant Health, Bristol Myers Squibb, Ribon Therapeutics; Advisory Board (Spouse) – Astellas, Otsuka Pharmaceuticals

Ben Jones: Stock Ownership/Employee: McKesson Corporation

Hagop Kantarjian, MD: Research/Grant Support: Abbvie, Agios, Amgen, Ariad, Astex, BMS, Cyclacel, Ddiichi-Sankyo, Immunogen, Jazz Pharma, Novartis, Pfizer; Advisory Board – Actinium; Speakers’ Bureau – AbbVie, Agios, Amgen, Immunogen, Orsinex, Pfizer, Takeda

Ira Klein, MD: Employee – Johnson & Johnson

Andrew Lee, MD: Employee – Texas Oncology

Howard Levine, PharmD: Speakers’ Bureau – Novartis, Seattle Genetics, Alexion, Sanofi

Daniel Lyons: Employee – Sanofi Genzyme, Aegerion

Aaron Lyss: Consultant – Amgen, Pfizer, Genentech, EMD Serono, BMS

Richard Maziarz, MD: Consultant – Novartis, Incyte, Celgene, Athersys

Jeff Mortier: Consultant – Genentech, Johnson & Johnson, Heron Therapeutics, Gilead

Todd Murphree, PharmD: Speakers’ Bureau – Eli Lilly, Exelixis, Takeda; Consultant – Takeda

Kristen O'Neill: Consultant - Farragut Partners

Mark O'Rourke: Employee – Takeda Pharmaceuticals

Kavita Patel, MD, MS: Employee – John Hopkins Health; Stocker Ownership (Spouse) – Tuple Health

Debra Patt, MD: Employee – Texas Oncology, MEDNAX; Board Membership – McKession Specialty Health

Jeffrey Patton, MD: Consultant – Amgen, BMS, Speakers’ Bureau – Abbvie, Genentech

Christine Roussel, PharmD: Consultant – Medisca/LP3 Educational

Jeffrey Vacirca, MD: Board Membership – Odonate Therapeutics, Spectrum Pharmaceuticals; Consultant – Amerisource Bergen Company

Harsha Vyas, MD: Advisory Board – ION LP

Sarah Walter: Consultant – Genentech, Gilead, Johnson & Johnson

Michelle Weiss: Speakers’ Bureau – Genentech, Merck, Amgen, Novartis

Clayton Wright: Employee – Takeda Pharmaceuticals

Dan Wygal: Employee – AstraZeneca

Lakshmi Aggarwal, MD, Richard Anderson, MD, Miriam Atkins, MD, Ray Bailey, RPh, Robert Baird, Ginger Blackmon, PharmD,  John Clagg, RPh, Kenny Cole, MD, MHCDS, Steven D'Amato, BS Pharm, BCOP, Christian Downs, Jesse Dresser, Amy Ellis, Jon Engstrom, Nick Ferreyros, Andrew Fisher, MPH, MA, Kathy Roy Gaughran, Rose Gerber, Bruce Gould, MD, William F. Hartsell, MD, Anshu Jain, MD, Susanne Johnson Berns, BSA, GGCP, Deborah Kamin, RN, PhD, Darryl Keef, Abra Kelson, Jonathan Levitt, Edward Licitra, MD, PhD, Jeff Lombardo, PharmD, BCOP, Stacey McCullough, PharmD, Kathy Niblick, Luke Nordquist, MD, Ted Okon, Stephen Orman, MD, Sonia Oskouei, PharmD, Ray Page, DO, PhD, Kashyap Patel,MD, Patrick Peters, Christine Pfaff, RPh, Lisa Poiry, Alti Rahman, John Robinson, Barry Russo, Fred Schnell, MD, Michael Schuh, Lee Schwartzberg, MD, Jeffery Sergent, Deborah Skojac, RN, MS, AOCN, Brad Tallamy, Caitlin Wilson, Kim Woofter, and Jax Zummo do not have any financial relationships with any commercial interests.

NACCME, Imedex and the Community Oncology Alliance Staff:

Chris Bolwell has stock ownership with GlaxoSmithKline

Susan Yarbrough, Jennifer Ilcyn, Tracy Havens, Michelle Bolger and Mary Kruczynski do not have any financial relationships with any commercial interests.

NACCME and Imedex require faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

Off-label/unapproved uses of drugs and/or devices will be disclosed prior to the start of each session.

Privacy Policy

NACCME and Imedex protect the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME, Imedex, and all joint sponsors will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME and Imedex maintain physical, electronic, and procedural safeguards that comply with federal regulations to guard your non-public personal information.

Copyright © 2019 by North American Center for Continuing Medical Education, LLC. and Imedex, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from NACCME. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

 

       

Outlook Outlook
iCal iCal
Google Google
Yahoo! Yahoo!
MSN MSN
Already Registered?

1225 New York Ave. NW, Suite 600, Washington, DC 20005 | 202-729-8147

Copyright Community Oncology Alliance | All Rights Reserved

User Agreement & Privacy Policy

Top